Ueno H
Department of Cardiology, Kyushu University School of Medicine.
Nihon Rinsho. 1998 Oct;56(10):2645-52.
Once myocardium is under hypoxia due to narrowing of coronary arteries, the myocardium produces angiogenic peptides such as fibroblast growth factors to develop collaterals to restore the blood supply to its ischemic region. Thus, if angiogenic growth factors are supplied exogenously, the development of collaterals should be facilitated, and may save myocardium from hypoxia, thereby enhancing heart function. In addition to the experiments using recombinant protein of angiogenic factors, recent reports showed that gene transfer of such angiogenic factors indeed restored blood supply into ischemic myocardium and enhanced its function, suggesting such approach being an effective new strategy for the treatment of ischemic heart disease. This brief review summarizes recent progress of angiogenic therapy.
一旦冠状动脉狭窄导致心肌处于缺氧状态，心肌就会产生血管生成肽，如成纤维细胞生长因子，以形成侧支循环来恢复其缺血区域的血液供应。因此，如果外源性提供血管生成生长因子，侧支循环的形成应该会得到促进，并且可能使心肌免受缺氧影响，从而增强心脏功能。除了使用血管生成因子重组蛋白的实验外，最近的报告表明，此类血管生成因子的基因转移确实恢复了缺血心肌的血液供应并增强了其功能，这表明这种方法是治疗缺血性心脏病的一种有效的新策略。这篇简短的综述总结了血管生成疗法的最新进展。
